DR. ANDREW D. LEAVITT, M.D.
Osteopathic Medicine at Parnassus Ave, San Francisco, CA

License number
California G65749
Category
Osteopathic Medicine
Type
Internal Medicine
License number
California G65749
Category
Osteopathic Medicine
Type
Hematology
Address
Address
505 Parnassus Ave, San Francisco, CA 94143
Phone
(415) 514-3432
(415) 514-3433 (Fax)
(415) 476-4029
(415) 476-4150 (Fax)

Personal information

See more information about ANDREW D. LEAVITT at radaris.com
Name
Address
Phone
Andrew Leavitt
4850 17Th St, San Francisco, CA 94117
Andrew Leavitt
3240 Oakwood Ct, Morgan Hill, CA 95037
Andrew Leavitt
1101 Laveta Ter APT 23, Los Angeles, CA 90026
Andrew Leavitt
2148 Grahn Dr, Santa Rosa, CA 95404
Andrew Leavitt
240 Livorna Heights Rd, Alamo, CA 94507

Professional information

Andrew Leavitt Photo 1

Professor At Ucsf

Position:
Professor at UCSF
Location:
San Francisco Bay Area
Industry:
Research
Work:
UCSF - Professor
Education:
Harvard Medical School 1979 - 1984
M.D., Medicine
University of Michigan 1975 - 1979
B.S., Zoology
Skills:
Science, Neuroscience, Immunohistochemistry, Molecular Biology, Western Blotting, Animal Models, Genetics, Cell Biology, Cell Culture


Andrew Leavitt Photo 2

Geologist At Arcadis

Position:
Geologist at ARCADIS
Location:
San Francisco Bay Area
Industry:
Environmental Services
Work:
ARCADIS - Geologist


Andrew D Leavitt Photo 3

Andrew D Leavitt, San Francisco CA

Specialties:
Internist
Address:
505 Parnassus Ave, San Francisco, CA 94143
1635 Divisadero St, San Francisco, CA 94115
Education:
Harvard Medical School - Doctor of Medicine
UCSF Medical Center - Fellowship - Blood Banking/Transfusion Medicine (Pathology)
UCSF Medical Center - Fellowship - Hematology and Oncology (Internal Medicine)
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine


Andrew David Leavitt Photo 4

Andrew David Leavitt, San Francisco CA

Specialties:
Internal Medicine, Hematology & Oncology, Hematology, Medical Oncology, General Practice, Pathology, Blood Banking & Transfusion Medicine, Hematology
Work:
University of California at San Francisco
521 Parnassus Ave, San Francisco, CA 94143
Education:
Harvard University(1984)


Andrew D Leavitt Photo 5

Dr. Andrew D Leavitt, San Francisco CA - MD (Doctor of Medicine)

Specialties:
Internal Medicine
Address:
Andrew D Leavitt MD
505 Parnassus Ave SUITE 100, San Francisco 94143
(415) 514-3432 (Phone)
Kaiser Permanente Medical Group
320 Lennon Ln, Walnut Creek 94598
(925) 906-2209 (Phone)
Certifications:
Internal Medicine, 1987
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Andrew D Leavitt MD
505 Parnassus Ave SUITE 100, San Francisco 94143
Kaiser Permanente Medical Group
320 Lennon Ln, Walnut Creek 94598
UCSF Medical Center
505 Parnassus Ave, San Francisco 94143
UCSF Medical Center at Mount Zion
1600 Divisadero St, San Francisco 94115
Education:
Medical School
Harvard Medical School
Graduated: 1984
University Of Michigan Hospitals
University Of California-San Francisco


Andrew Leavitt Photo 6

Naphthols Useful In Antiviral Methods

US Patent:
6140368, Oct 31, 2000
Filed:
May 4, 1998
Appl. No.:
9/072484
Inventors:
George L. Kenyon - San Francisco CA
Margaret Stauber - Germantown MD
Karl Maurer - Ross CA
Dolan Eargle - San Francisco CA
Angelika Muscate - Loerrach, DE
Andrew Leavitt - San Francisco CA
Diana C. Roe - Newark CA
Todd J. A. Ewing - San Francisco CA
Allan G. Skillman - San Francisco CA
Edward Arnold - Belle Mead NJ
Irwin D. Kuntz - Greenbrae CA
Malin Young - San Francisco CA
Assignee:
The Regents of the University of California - Oakland CA
Rutgers, The University of New Jersey - New Brunswick NJ
International Classification:
A61K 31175
US Classification:
514593
Abstract:
The present invention relates to a novel class of compounds that are potent inhibitors of HIV reverse transcriptase and HIV integrase. In addition to being multienzyme inhibitors, the inventive compounds of the present invention are remarkable in at least two other respects. First, they do not appear to be toxic to cells at typical therapeutic concentrations. Second, they appear to be equally effective against mutant strains of HIV reverse transcriptase commonly found in patients who have developed resistance to current reverse transcriptase inhibitors. Because the inventive compounds show promise in combatting viral resistance and are potent inhibitors of both HIV reverse transcriptase and integrase, they are ideal candidates for use in combination with existing therapies or alone in treating AIDS or HIV infection.